Clinical Trial Update: A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL) [Phase 2]

View source ↗

Summary

Phase II study evaluating oral panobinostat (LBH589) in combination with rituximab for diffuse large B-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Panobinostat (Panobinostat)
• Rituximab (rituximab)

Snippet

Sponsor: Sarit Assouline | Conditions: Diffuse Large B Cell Lymphoma | Phase 2 | Status: COMPLETED